TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NTRK1/TrkA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | NTRK1/TrkA ECD-Fc Fusion Protein & Kinase Domain Wild-Type. High purity (>95%), Endotoxin <1 EU/µg. Sequence verified. HEK293 expressed (native glycosylation). Theoretical MW confirmed. | View NTRK1 Products |
| Antigen (Resistance Mutants) | NTRK1/TrkA Kinase Domain Mutant Proteins (G595R, F589L, G667C). Sequence verified, >95% purity. For selectivity and resistance profiling of next-gen inhibitors. | View NTRK1 Products |
| Gene Delivery | NTRK1/TrkA Premade Lentivirus Particles. Full-length ORF for stable cell line construction in HEK293, Ba/F3, or neuroblastoma models. Preserves native conformation and supports fusion oncogene (e.g., ETV6-NTRK1) expression. | View NTRK1 Products |
| Benchmark Ab | Anti-NTRK1/TrkA Neutralizing Antibody (recombinant positive control). Suitable for binding blockade, competition assays (e.g., Larotrectinib-competitive), and high-throughput screening calibration. | View NTRK1 Products |
| Validator | NTRK1/TrkA siRNA Set. For knockdown verification, off-target screening, and specificity controls in cellular assays (e.g., phosphorylation, internalization). | View NTRK1 Products |
| Related Target A | NGF (Nerve Growth Factor). Primary ligand for TrkA; essential for constructing competitive binding/blocking assays and pain pathway validation. | View NGF Products |
| Related Target B | NTRK2/TrkB. Critical counter-screen to avoid CNS toxicity (dizziness, weight gain, ataxia). Pan-TRK selectivity profiling required for next-gen inhibitors. | View NTRK2 Products |
| Related Target C | NTRK3/TrkC. Subfamily selectivity assay; distinguishes TrkA-specific from pan-TRK modalities. High homology to NTRK1. | View NTRK3 Products |
| Related Target D | ROS1. Structurally related kinase often co-targeted in NSCLC (e.g., Entrectinib, Repotrectinib). Cross-resistance analysis and multi-kinase profiling. | View ROS1 Products |
| Related Target E | ALK. High structural homology in kinase domain; similar solvent-front resistance mutations (ALK G1202R). Useful for off-target liability and cross-resistance studies. | View ALK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Acquired resistance mutations (solvent front G595R/G667C, gatekeeper F589L) | NTRK1 Kinase Domain Mutant Proteins (G595R, F589L, G667C) >95% purity, sequence verified by mass spec. HEK293 expressed for native folding, enabling precise biochemical IC50 profiling. |
| Pan-TRK vs. selective screening (avoid neurotoxicity from TrkB/TrkC) | Orthologous TRK Panel: Human NTRK1/2/3 Kinase Domains expressed in HEK293. Strict purity verification for accurate selectivity indexing. |
| Blood-brain barrier penetration models (CNS metastases) | Lentivirus for stable cell lines with full-length NTRK1 or ETV6-NTRK1 fusion, enabling Ba/F3 proliferation assays and MDR1-MDCK permeability studies. |
| False positives / off-target binding | Validated siRNA set for target-specificity confirmation; benchmark antibodies for orthogonal verification. Endotoxin <1 EU/µg for clean cell assays. |
| Lack of validated positive controls | Clinical benchmark biosimilars/inhibitor controls (e.g., anti-NTRK1 neutralizing antibody) included for assay calibration and competition binding. |
Live NTRK1/TrkA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NTRK1/TrkA therapeutics has shifted from first-generation pan-TRK inhibitors (larotrectinib, entrectinib) to addressing acquired resistance. First-generation agents transformed treatment of NTRK fusion-positive solid tumors (tissue-agnostic) but are limited by solvent-front mutations (G595R) and gatekeeper mutations (F589L). The next wave targets next-generation macrocyclic kinase inhibitors (e.g., repotrectinib, selitrectinib) that overcome resistant mutants, CNS-penetrant scaffolds for brain metastases, and novel modalities including PROTACs, selective monoclonal antibodies for neuropathic pain, TRK-targeting ADCs, and bispecifics. Liquid biopsy companion diagnostics using broad NGS panels continue to expand patient identification in rare, histology-agnostic indications. The market is rapidly evolving toward resistance management, isoform selectivity (avoiding TrkB/C toxicity), and combination therapies with immune checkpoint inhibitors or chemotherapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| First-Gen TRK Inhibitors | Bayer/Loxo (Larotrectinib), Roche/Ignyta (Entrectinib) | TRK Fusion+ Solid Tumors (salivary, infantile fibrosarcoma, NSCLC, thyroid) | Pan-TRK Selectivity Panel (Need NTRK1/2/3 WT proteins) |
| Next-Gen TRK Inhibitors | BMS/Turning Point (Repotrectinib), Bayer/Loxo (Selitrectinib) | Resistant Solid Tumors, CNS metastases | Resistance Mutation Assay (Need G595R/F589L/G667C mutant proteins) |
| Monoclonal Antibody (Pain) | Pfizer, Regeneron | Neuropathic Pain, Osteoarthritis | Binding/Blocking Assays (Need high-purity ECD-Fc with native glycosylation) |
| PROTAC / Degrader | Early-stage Biotechs | Refractory Cancers | Ternary Complex Formation (Need purified kinase domains & ligases) |
| Bispecifics | Various | Targeted Oncology | Heterodimer Validation (Need cross-reactive Pan-TRK panels) |
| TRK-Targeting ADCs | Emerging Biotech | NTRK1-amplified Cancers | Internalization Assay (Need ECD-Fc protein and lentivirus for stable cell lines) |
| Combination Therapy | Various | Overcoming Acquired Resistance | Cell Line Construction (Need lentivirus for stable ETV6-NTRK1 Ba/F3 cells) |
Strategic Molecular Differentiation & Assay Considerations
To develop best-in-class NTRK1 therapeutics, molecular differentiation must address the following dimensions, each with corresponding assay needs:
- Affinity & Kinetics: SPR/BLI binding kinetics; competitive kinase activity assays. TarMart provides WT and mutant kinase domains (>95% purity, HEK293 expressed).
- Subfamily Selectivity: NTRK1 vs NTRK2 vs NTRK3 counter-screen using orthologous protein panel.
- Resistance Coverage: Biochemical IC50 profiling against G595R, F589L, G667C mutants.
- CNS Penetration: MDR1-MDCK permeability and Ba/F3-ETV6-NTRK1 cell proliferation assays.
- Internalization (for ADCs): Flow cytometry and high-content imaging using lentivirus-generated stable cell lines.
- Safety & Off-target: Kinase selectivity panel including ALK, ROS1, FLT3; plus siRNA knockdown confirmation.
The comprehensive TarMart toolkit—covering antigens, mutants, gene delivery, benchmark antibodies, and validators—enables seamless progression from biochemical to cellular assays, supporting both established and emerging modalities.